PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
18.34%
Net income growth above 1.5x TRVN's 7.99%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-12.79%
Both reduce yoy D&A, with TRVN at -22.46%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
35.67%
Well above TRVN's 14.71% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
-6.19%
Both cut yoy SBC, with TRVN at -37.05%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
947.27%
Slight usage while TRVN is negative at -35.91%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
844.13%
AP growth of 844.13% while TRVN is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-18.50%
Negative yoy usage while TRVN is 365.05%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-6.19%
Negative yoy while TRVN is 3.13%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
46.02%
Some CFO growth while TRVN is negative at -0.91%. John Neff would note a short-term liquidity lead over the competitor.
81.40%
CapEx growth well above TRVN's 92.42%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-34.69%
Both yoy lines negative, with TRVN at -23.40%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
80.57%
We have mild expansions while TRVN is negative at -14.14%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
-99.82%
Both yoy lines negative, with TRVN at -72.50%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.